WuXi AppTec Co. Ltd (WUXAY) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN US98260P1030
WuXi AppTec Co. Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 39.24 bn CNY | 45.46 bn CNY |
| Gross profit | 16.28 bn CNY | 21.65 bn CNY |
| Operating income | 11.58 bn CNY | 17.00 bn CNY |
| EBIT | 11.76 bn CNY | 24.21 bn CNY |
| Net income | 9.45 bn CNY | 19.15 bn CNY |
| Diluted EPS – continuing operations | 3.26 CNY | 6.70 CNY |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About WuXi AppTec Co. Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
More stocks
- SK Square Co Ltd (402340.KS)
- Kinder Morgan (KMI)
- Canadian National Railway Co (CNR.TO)
- Hilton Worldwide (HLT)
- SoftBank Corp (9434.T)
- Royal Caribbean Group (RCL)
- Assicurazioni Generali SpA (G.MI)
- Cummins (CMI)
- Norfolk Southern (NSC)
- Manulife Financial Corp (MFC.TO)
- General Motors (GM)
- Schlumberger (SLB)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.